
Lantern Pharma LTRN
$ 2.52
4.13%
Annual report 2025
added 03-30-2026
Country |
|
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
10.9 M |
Market Cap[1] |
$ 27.5 M |
EBITDA (LTM) |
$ -16.9 M |
P/E (LTM) |
-1.48 |
P/S (LTM) |
- |
EPS (LTM) |
-1.63 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.85 | 3.22 % | $ 9.26 B | Nasdaq Capital Market | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 330.55 | -0.85 % | $ 43.3 B | Nasdaq Global Select Market,SPB | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aligos Therapeutics
ALGS
|
$ 7.51 | 1.21 % | $ 74.2 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | ||
|
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 21.68 | - | $ 1.01 B | Nasdaq Global Select Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 99.49 | 0.02 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Burford Capital Limited
BUR
|
$ 4.79 | 1.06 % | $ 771 M | NYSE | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 3.46 | 1.62 % | $ 348 M | Nasdaq Global Select Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 3.17 | -2.16 % | $ 5.22 M | NYSE American | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 1.5 | -3.23 % | $ 386 M | Nasdaq Global Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Aquestive Therapeutics
AQST
|
$ 4.24 | -0.12 % | $ 453 M | Nasdaq Global Market | ||
|
Arcutis Biotherapeutics
ARQT
|
$ 24.54 | -0.18 % | $ 3.12 B | Nasdaq Global Select Market,SPB | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.48 | -1.01 % | $ 394 M | Nasdaq Global Select Market | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Clearside Biomedical
CLSD
|
- | - | $ 25.3 M | Nasdaq Global Market | ||
|
Celldex Therapeutics
CLDX
|
$ 33.97 | 0.3 % | $ 2.26 B | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
CNS Pharmaceuticals
CNSP
|
$ 2.67 | -2.91 % | $ 1.18 M | Nasdaq Capital Market | ||
|
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.